BIOMAT Database Logo BIOMAT Database Logo

Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass. 1996

E Ovrum

UI MeSH Term Description Entries
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D004804 Eosinophils Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. Eosinophil
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

E Ovrum
Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass.
August 1994, The Annals of thoracic surgery,
E Ovrum
Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.
July 1996, Artificial organs,
E Ovrum
Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass.
May 1997, The Annals of thoracic surgery,
E Ovrum
Heparin-coated cardiopulmonary bypass circuits.
April 1994, Journal of cardiothoracic and vascular anesthesia,
E Ovrum
Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass.
April 1991, Artificial organs,
E Ovrum
Use of heparin-coated cardiopulmonary bypass.
September 1993, The Annals of thoracic surgery,
E Ovrum
Improving cardiopulmonary bypass: heparin-coated circuits.
December 2003, The journal of extra-corporeal technology,
E Ovrum
Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
September 1999, Panminerva medica,
E Ovrum
Quantitative evaluation of heparin-coated versus non-heparin-coated bypass circuits during cardiopulmonary bypass.
September 1999, The journal of extra-corporeal technology,
E Ovrum
Heparin-coated cardiopulmonary bypass circuits: current status.
September 2001, Perfusion,
Copied contents to your clipboard!